Search Results

Your search for Seema A. Bhat, MD, and Jennifer A. Woyach, MD matches 2 pages

Showing 1 - 2

By Seema A. Bhat, MD, and Jennifer A. Woyach, MD / November 25, 2020 - Supplement: Hematologic Oncology Almanac

Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL

The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the treatment of patients with chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on...

leukemia

lymphoma

By Seema A. Bhat, MD, and Jennifer A. Woyach, MD / August 25, 2020

Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL

The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the tre atment of chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on studies where...

Apr

Today In Oncology

Search Results

Your search for Seema A. Bhat, MD, and Jennifer A. Woyach, MD matches 2 pages

Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL

Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer

Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved

Potential Protective Effects of Aspirin Against Colorectal Cancer